AI Article Synopsis

  • Major challenges in studying CD4+ effector cells and regulatory T cells (Tregs) arise from both cell types expressing CD25 and the necessity to analyze the forkhead box p3 marker in nonviable cells.
  • The research highlights the utility of CD134 (OX40) combined with CD25 as a reliable method to distinguish live CD4+ effector cells from Tregs, particularly during adjuvant arthritis in rats.
  • Findings indicate that CD134 and CD25 coexpression reliably identifies activated suppressive Tregs, while different lymph node locations show distinct functional variations in CD4+ T cell populations throughout the course of experimental arthritis.

Article Abstract

Major problems in the analysis of CD4+ effector cell and regulatory T cell (Treg) populations in an activated immune system are caused by the facts that both cell types can express CD25 and that the discriminatory marker forkhead box p3 can only be analyzed in nonviable (permeabilized) cells. Here, we show that CD134 (OX40) can be used as a discriminatory marker combined with CD25 to isolate and characterize viable CD4+ effector cells and Tregs. Before and during adjuvant arthritis in rats, coexpression of CD134 and CD25 identified activated Tregs consistently, as these T cells proliferated poorly to disease-associated antigens and were suppressive in vitro and in vivo. Depending on the time of isolation and location, CD4+ T cell populations expressing CD134 or CD25 contained effector/memory T cells. Analysis of the function, phenotype, and amount of the CD4+ T cell subsets in different lymph node stations revealed spatiotemporal differences in effector cell and Treg compartments during experimental arthritis.

Download full-text PDF

Source
http://dx.doi.org/10.1189/jlb.0607436DOI Listing

Publication Analysis

Top Keywords

experimental arthritis
8
cd4+ effector
8
effector cell
8
cell treg
8
discriminatory marker
8
cd134 cd25
8
cd4+ cell
8
cell
6
cells
5
cd25
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!